Particle.news
Download on the App Store

Repurposed Kidney Drug Triggers Egg Development in Small POI Trial, Science Study Reports

Researchers target ovarian fibrosis to reset the ovarian stroma, setting up larger controlled trials.

Overview

  • The University of Hong Kong–led team reports that finerenone, approved for diabetes‑related chronic kidney disease, helped dormant follicles produce mature eggs in a 14‑patient pilot.
  • Participants received 20 mg of finerenone twice weekly, and in several cases doctors retrieved mature oocytes that were successfully fertilized in vitro.
  • Preclinical mouse studies showed the drug reduced excess collagen, softened ovarian tissue, restored Kit ligand signaling, and enabled follicle growth.
  • Finerenone was identified after screening nearly 1,300 FDA‑approved compounds for boosting Kit ligand in ovarian stromal cells.
  • The findings, published in Science (2026; DOI: 10.1126/science.adz4075), are early proof of concept for premature ovarian insufficiency, a condition affecting up to about 3% of women under 40, and experts stress the need for larger, controlled trials to confirm safety and efficacy.